Protein and energy metabolism response to the initial dose of infliximab in children with Crohn's disease

Inflammatory Bowel Diseases

Volumn 13, Issue 6, 2007, Pages 737-744

  Steiner, Steven J ^a   Pfefferkorn, Marian D ^a   Fitzgerald, Joseph F ^a   Denne, Scott C ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's disease; Infliximab; Protein synthesis; Proteolysis; TNF

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; INFLIXIMAB; ISOTOPE; LEUCINE C 1-13; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PHENYLALANINE D5; PREDNISONE; PROTON PUMP INHIBITOR; TYROSINE D2; TYROSINE D4; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; CROHN DISEASE; DIET RESTRICTION; ENERGY EXPENDITURE; ENERGY METABOLISM; FEMALE; HUMAN; HYDROXYLATION; MALE; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REST; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CALORIMETRY, INDIRECT; CARBON ISOTOPES; CHILD; CROHN DISEASE; ENERGY METABOLISM; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCINE; MALE; PHENYLALANINE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34250336793     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20102     Document Type: Article

References (36)

1. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology. 1993;105:681-691.
2. Kirschner BS. Growth and development in chronic inflammatory bowel disease. Acta Paediatr Scand Suppl. 1990;366:98-104; discussion 5.
3. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease [see Comment]. J Pediatr Gastroenterol Nutr. 1993;16:373-380.
4. Layden T, Rosenberg F, Nemchausky G, Elson C, Rosenberg I. Reversal of growth arrest in adolescents with Crohn's disease after parenteral alimentation. Gastroenterology. 1976;70:1017-1021.
5. Kirschner BS, Klich JR, Kalman SS, deFavaro MV, Rosenberg IH. Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology. 1981;80:10-15.
6. Davies G, Evans CM, Shand WS, Walker-Smith JA. Surgery for Crohn's disease in childhood: influence of site of disease and operative procedure on outcome. Br J Surg. 1990;77:891-894.
7. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988;167:1211-1227.
8. Warren RS, Starnes HF Jr, Gabrilove JL, Oettgen HF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg. 1987;122:1396-1400.
9. Elborn JS, Cordon SM, Western PJ, Macdonald IA, Shale DJ. Tumour necrosis factor-alpha, resting energy expenditure and cachexia in cystic fibrosis. Clin Sci (Colch). 1993;85:563-568.
10. Starnes HF Jr, Warren RS, Jeevanandam M, et al. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest. 1988;82:1321-1325.
11. Van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR, Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol. 1991;261:E457-465.
12. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
13. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
14. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center [see Comment]. Am J Gastroenterol. 2003;98:104-111.
15. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease [see Comment]. J Pediatr Gastroenterol Nutr. 2003;36:632-636.
16. Denne SC, Kalhan SC. Glucose carbon recycling and oxidation in human newborns. Am J Physiol. 1986;251:E71-77.
17. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
18. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci. 1959;82:420-430.
19. Tserng KY, Kalhan SC. Calculation of substrate turnover rate in stable isotope tracer studies. Am J Physiol. 1983;245:E308-311.
20. Denne SC, Kalhan SC. Leucine metabolism in human newborns. Am J Physiol. 1987;253:E608-615.
21. Castellino P, Luzi L, Simonson DC, Haymond M, DeFronzo RA. Effect of insulin and plasma amino acid concentrations on leucine metabolism in man. Role of substrate availability on estimates of whole body protein synthesis. J Clin Invest. 1987;80:1784-1793.
22. Flakoll PJ, Kulaylat M, Frexes-Steed M, et al. Amino acids augment insulin's suppression of whole body proteolysis. Am J Physiol. 1989;257(6 Pt 1):E839-847.
23. Thompson GN, Pacy PJ, Merritt H, et al. Rapid measurement of whole body and forearm protein turnover using a [2H5]phenylalanine model. Am J Physiol. 1989;256(5 Pt 1):E631-639.
24. Nair KS, Ford GC, Ekberg K, Fernqvist-Forbes E, Wahren J. Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients. J Clin Invest. 1995;95:2926-2937.
25. Kien CL, Zipf WB, Horswill CA, Denne SC, McCoy KS, O'Dorisio TM. Effects of feeding on protein turnover in healthy children and in children with cystic fibrosis [see Comment]. Am J Clin Nutr. 1996;64:608-614.
26. Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut. 1997;41:203-208.
27. Clark SE, Karn CA, Ahlrichs JA, et al. Acute changes in leucine and phenylalanine kinetics produced by parenteral nutrition in premature infants. Pediatr Res. 1997;41(4 Pt 1):568-574.
28. Powell-Tuck J, Garlick PJ, Lennard-Jones JE, Waterlow JC. Rates of whole body protein synthesis and breakdown increase with the severity of inflammatory bowel disease. Gut. 1984;25:460-464.
29. Thomas AG, Miller V, Taylor F, Maycock P, Scrimgeour CM, Rennie MJ. Whole body protein turnover in childhood Crohn's disease. Gut. 1992;33:675-677.
30. Tracey KJ, Legaspi A, Albert JD, et al. Protein and substrate metabolism during starvation and parenteral refeeding. Clin Sci (Colch). 1988;74:123-132.
31. Pacy PJ, Garrow JS, Ford GC, Merritt H, Halliday D. Influence of amino acid administration on whole-body leucine kinetics and resting metabolic rate in postabsorptive normal subjects. Clin Sci (Colch). 1988;75:225-231.
32. Goulet O, DePotter S, Salas J, et al. Leucine metabolism at graded amino acid intakes in children receiving parenteral nutrition. Am J Physiol. 1993;265(4 Pt 1):E540-546.
33. Fong Y, Matthews DE, He W, Marano MA, Moldawer LL, Lowry SF. Whole body and splanchnic leucine, phenylalanine, and glucose kinetics during endotoxemia in humans. Am J Physiol. 1994;266(2 Pt 2):R419-425.
34. Barot LR, Rombeau JL, Steinberg JJ, Crosby LO, Feurer ID, Mullen JL. Energy expenditure in patients with inflammatory bowel disease. Arch Surg. 1981;116:460-462.
35. Zoli G, Katelaris PH, Garrow J, Gasbarrini G, Farthing MJ. Increased energy expenditure in growing adolescents with Crohn's disease. Dig Dis Sci. 1996;41:1754-1759.
36. Varille V, Cezard JP, de Lagausie P, et al. Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 1996;23:13-19.